



---

**Medicago to participate at prominent U.S. vaccine development conference**

**Quebec City, Quebec, August 13, 2008** — Medicago Inc. (TSX-V: MDG) today announced that it will be presenting an update of its development of H5N1 vaccines generated from plant-made VLPs and unique technology platform, at the Targeted Immunotherapeutics and Vaccine Summit. This conference will be held from August 13-15, 2008, at the Royal Sonesta Hotel, Cambridge, Massachusetts.

Manon Couture, Ph.D., Project Leader, Product Development and Innovation will deliver a presentation on "Innovative Influenza Virus-Like Particles Provides Protection against an H5N1 Challenge" in a session entitled "Innovating Vaccine Development," on Thursday August 14, 2008 at 10:45 a.m. EDT.

Additional information about the Targeted Immunotherapeutics and Vaccines Summit, including the full scientific program, can be viewed at [www.healthtech.com](http://www.healthtech.com)

**About Medicago**

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at [www.medicago.com](http://www.medicago.com).

***Forward-Looking Statements***

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

- 30 -

The TSX Venture Exchange assumes no responsibility for the content or accuracy of this press release

**Contact:**

**Medicago, Inc.**  
Andy Sheldon  
President and CEO  
(418) 658-9393

**Investor relations**

**The Equicom Group Inc.**  
Arianna Vanin  
(514) 844-4680  
[avanin@equicomgroup.com](mailto:avanin@equicomgroup.com)